82525-03-9

Upstream product

• 93300-81-3 β-(m-methoxyphenyl)-α-phenylpropionic acid 
• 93273-52-0 3-(m-methoxyphenyl)-2-phenyl-1-tosyloxypropane 
• 93273-50-8 methyl β-(m-methoxyphenyl)-α-phenylpropionate 
• 76570-03-1 4-(3-methoxyphenyl)-3-phenylbutanoic acid 
• 93273-53-1 4-(m-methoxyphenyl)-3-phenylbutyronitrile 
• 93273-51-9 3-(m-methoxyphenyl)-2-phenylpropan-1-ol 

Downstream Products

• 93273-54-2 1,3-cis-1-hydroxy-3-phenyl-6-methoxytetralin 
• 93273-56-4 6-methoxy-3-phenyl-1-tetralin 
• 93273-55-3 1-(o-hydroxyphenyl)-6-methoxy-3-phenyltetralin 
• 93300-82-4 1-(p-hydroxyphenyl)-6-methoxy-3-phenyltetralin 
• 93273-57-5 6-methoxy-3,4-dihydronaphthalene 
• 93273-58-6 1-(3-dimethylaminopropyl)-3-phenyl-6-methoxy-3,4-dihydronaphthalene 

Relevant academic research and scientific papers

1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES

Compounds of the formula STR1 and pharmaceutically acceptable salt thereof, wherein R 2 is selected from hydroxy and lower alkoxy, R 5 is lower alkyl, and R 11 and R 12 are independently selected from hydrogen, halo, hydroxy, methoxy, and lower alkyl, are selective . alpha.. sub.2 adrenergic receptor antagonists useful in the treatment of glaucoma.

1-aminomethyl-1,2,3,4-tetrahydronaphthalenes

The present invention provides compounds of the formula STR1 or a pharmaceutically acceptable salt thereof wherein R1 is selected from hydrogen, halo, lower alkyl, lower alkoxy, or thioalkoxy; and R2 is lower alkoxy; or R1 and R2 together form a methylenedioxy or ethylenedioxy ring; R3 and R4 are independently selected from hydrogen, hydroxy, lower alkyl, lower alkoxy, lower alkylthio, (lower alkyl)amino, (lower alkylsulfonyl)amino, and halo; and R7 is selected from the group consisting of 2- or 3-thienyl, 2- or 3-furyl, and STR2 where R13 and R14 are independently selected from the group consisting of hydrogen, hydroxy, halogen, amino, lower alkyl, lower alkoxy, lower alkylthio, methylenedioxy, or ethylenedioxy. The compounds of the present invention selectively inhibit α2 -adrenergic receptors as well as inhibit the uptake of biogenic amines and are thus useful in the treatment of certain cardiovascular and psychiatric disorders.

Studies on Antifertility Agents: Part XLII - Synthesis and Antifertility Study of 6-Methoxy-3-phenyl-1-tetralin

LAH reduction of methyl β-(m-methoxyphenyl)-α-phenylpropionate (2) gives propanol 3 which after treatmeant with p-TsCl is reacted with KCN to yield the butyronitrile (5) and a mixture of isomeric propenes (6).Alkaline hydrolysis of 5 gives 7 which on cyclisation with PCl5-SnCl4 affords 6-methoxy-3-phenyl-1-tetralone (8).Reaction of Me2N(CH2)3MgCl with 8 furnishes the corresponding 1-substituted dihydronaphthalene (12).KBH4 reduction of 8 gives preferably 1,3-cis-tetralol (9a) as indicated by 13C-NMR and PMR data, NOE results and also by 13C-NMR data of its acetyl derivative (10). Condensation of 9a with PhOH-AlCl3 gives a mixture of products from which cis/trans-mixture of 1-(p-hydroxyphenyl) (13) and 1-(o-hydroxyphenyl) (14) derivatives and dialin (15) are obtained.Acetylation of 13 (a mixture of two isomers in 55:45 proportion as shown by GLC) and 14 with Ac2O-pyridine gives the corresponding acetoxy derivatives (16 and 17).Compound 13 on condensation with β-chloroethylpyrrolidine affords the title compound (18).In female albino rats, compound 18 does not prevent pregnancy at 10 mg/kg dose.As 18 is a mixture no inference can be had about the receptor site.